GC Green Cross announced on February 6 that it has submitted a marketing authorization application for its intraventricular formulation of a Hunter syndrome treatment, "Hunterase ICV," to the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru.


Exterior view of the Green Cross headquarters in Yongin, Gyeonggi Province. Green Cross

Exterior view of the Green Cross headquarters in Yongin, Gyeonggi Province. Green Cross

View original image

Hunterase ICV is a treatment in which the drug is administered directly into the cerebral ventricles through a device implanted in the patient's head. It was developed with the aim of improving central nervous system (CNS) symptoms, which were difficult to address with systemic administration. Around 70% of Hunter syndrome patients are severe cases accompanied by CNS damage, and it is known that as the disease progresses, their cognitive function declines and their life expectancy shortens. Hunter syndrome is a congenital rare disease caused by a deficiency of the enzyme IDS (Iduronate-2-sulfatase), leading to skeletal abnormalities and cognitive decline. It occurs in approximately 1 out of every 100,000 to 150,000 male children.


GC Green Cross explained that in clinical trials conducted in Japan, Hunterase ICV significantly reduced levels of heparan sulfate, a key causative substance of CNS damage. The treatment also showed effects in improving or stabilizing patients' developmental age. In addition, in a five-year long-term follow-up, heparan sulfate levels remained consistently low, and the decline in cognitive function was delayed or improved.


Hunterase ICV is currently being sold in Japan and Russia, and in August last year the company also completed a marketing authorization application to the Ministry of Food and Drug Safety in Korea. The company plans to gradually expand the number of approved countries to regions including Southeast Asia, the Middle East, and Central and South America.



Lee Jaewoo, Head of Development at GC Green Cross, said, "Hunterase ICV is an innovative therapy that offers a new treatment alternative for patients with severe Hunter syndrome," adding, "We will continue our research and development efforts and the expansion of global supply to address unmet medical needs in the field of rare diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing